絞り込み

16506

広告

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France.

著者 Pignata M , Chouaid C , Le Lay K , Luciani L , McConnachie C , Gordon J , Roze S
Clinicoecon Outcomes Res.2017 ; 9():655-668.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (34view , 0users)

Full Text Sources

Miscellaneous

Lung cancer has the highest mortality rate of all cancers worldwide. Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and has an extremely poor prognosis. Afatinib is an irreversible ErbB family blocker designed to suppress cellular signaling and inhibit cellular growth and is approved in Europe after platinum-based therapy for squamous NSCLC. The objective of the present analysis was to evaluate the cost-effectiveness of afatinib after platinum-based therapy for squamous NSCLC in France.
PMID: 29123418 [PubMed]
印刷用ページを開く Endnote用テキストダウンロード